¼¼°èÀÇ »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå
Bioresorbable Stents
»óǰÄÚµå : 1526338
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 125 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

»ýüÈí¼ö¼º ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2030³â±îÁö 12¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 5¾ï 5,440¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â »ýüÈí¼ö¼º ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 12¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2023-2030³â°£ CAGRÀº 12.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. Æú¸®¸Ó ±â¹Ý »ýüÈí¼ö¼º ½ºÅÙÆ®´Â º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀ̸ç, CAGR 12.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9¾ï 520¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±Ý¼Ó ±â¹Ý »ýüÈí¼ö¼º ½ºÅÙÆ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 10.2%·Î ÃßÁ¤µË´Ï´Ù.

¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

»ýüÈí¼ö¼º Ç÷°ü ºñ°è(BVS)¶ó°íµµ ºÒ¸®´Â »ýüÈí¼ö¼º ½ºÅÙÆ®´Â ÁßÀçÀû ½ÉÀ庴Çп¡¼­ Áß¿äÇÑ Áøº¸¸¦ »ó¡ÇÕ´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â ½Ã¼ú ÈÄ µ¿¸ÆÀ» ÀϽÃÀûÀ¸·Î ÁöÁöÇÏ°í ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¼­¼­È÷ ¿ëÇØµÇ¾î ÀÚ¿¬ Ç÷°üÀ» ³²±æ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ü³»¿¡ ¿µ±¸ÀûÀ¸·Î ³²¾ÆÀÖ´Â ±âÁ¸ÀÇ ±Ý¼Ó ½ºÅÙÆ®¿Í´Â ´Þ¸®, »ýüÈí¼ö¼º ½ºÅÙÆ®´Â Æú¸®À¯»ê(PLA)°ú °°ÀÌ ÀÚ¿¬ÀûÀ¸·Î ºÐÇØµÇ¾î ü³»¿¡ Èí¼öµÇ´Â ¹°Áú·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀϽÃÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ ¸¸¼º ¿°Áõ ¹× Èıâ Ç÷ÀüÁõ°ú °°Àº ¿µ±¸Àû ÀÓÇöõÆ®¿¡ ¼ö¹ÝµÇ´Â Àå±âÀûÀÎ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ »ýüÈí¼ö¼º ½ºÅÙÆ®´Â °ü»óµ¿¸Æ Áúȯ Ä¡·á¿¡ È¿°úÀûÀÓÀÌ ÀÔÁõµÇ¾úÀ¸¸ç, ±Ý¼Ó ½ºÅÙÆ®¿¡ ÇÊÀûÇÏ´Â °á°ú¸¦ º¸¿©ÁÖ¸ç, ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Ç÷°üÀÇ º»·¡ ±â´É°ú À¯¿¬¼ºÀ» ȸº¹ÇÏ´Â ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù.

»ýüÈí¼ö¼º ½ºÅÙÆ®ÀÇ °³¹ßÀº ±¤¹üÀ§ÇÑ Á¶»ç¿Í ±â¼ú Çõ½ÅÀ» ÅëÇØ ÃßÁøµÇ¾î ¿Ô½À´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â Ç÷°ü ¼ºÇü¼ú ÈÄ Áß¿äÇÑ Ä¡À¯ ±â°£ µ¿¾È µ¿¸Æ¿¡ ÇÊ¿äÇÑ ±â°èÀû ÁöÁö·ÂÀ» Á¦°øÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ½ºÅÙÆ®´Â Á¡Â÷ ¼º´ÉÀÌ ÀúÇϵǾî Àå±âÀûÀÎ ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ¶ÇÇÑ, »ýüÈí¼ö¼º ½ºÅÙÆ®´Â Á¾Á¾ Ç×Áõ½ÄÁ¦·Î ÄÚÆÃµÇ¾î ÀçÇùÂø, Áï µ¿¸ÆÀÇ ÀçÇùÂøÀ» ´õ¿í ¿¹¹æÇÕ´Ï´Ù. ±â°èÀû ÁöÁö¿Í ¾à¹° Àü´ÞÀÇ ÀÌÁß ±â´ÉÀº ȯÀÚÀÇ Ä¡·á °á°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ Ã·´Ü ¿µ»ó ó¸® ±â¼ú°ú Á¤¹Ð °øÇÐÀÇ »ç¿ëÀº ÀÌ·¯ÇÑ ½ºÅÙÆ®ÀÇ ¹èÄ¡¿Í È¿°ú¸¦ °³¼±ÇÏ¿© ´õ ¸¹Àº ȯÀÚ¿Í ÀÓ»ó »óȲ¿¡¼­ ½ÇÇà °¡´ÉÇÑ ¼±ÅÃÀÌ µÉ ¼ö ÀÖµµ·Ï °³¼±µÇ¾ú½À´Ï´Ù.

»ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, Àü ¼¼°èÀûÀ¸·Î ½ÉÇ÷°ü Áúȯ, ƯÈ÷ °ü»óµ¿¸Æ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀ̰í Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. µÑ°, ȯÀÚ¿Í ÀÇ·áÁø »çÀÌ¿¡¼­ ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 »ýüÈí¼ö¼º ½ºÅÙÆ®ÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ºÅÙÆ®´Â ±âÁ¸ ¹æ½Ä¿¡ ´ëÇÑ À¯¸ÁÇÑ ´ë¾ÈÀ» Á¦°øÇϸç, º¸´Ù ÃÖ¼Ò Ä§½ÀÀûÀÎ °³ÀÔÀ» Ãß±¸ÇÏ´Â Ãß¼¼¿¡ ºÎÇÕÇÕ´Ï´Ù. ¼Â°, »ýü Àç·á¿Í ½ºÅÙÆ® ¼³°èÀÇ ±â¼úÀû Áøº¸·Î ÀÎÇØ »ýüÈí¼ö¼º ½ºÅÙÆ®ÀÇ ¼º´É°ú ¾ÈÀü¼ºÀÌ Çâ»óµÇ¾î ÀÓ»óÀÇ¿¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡¿À°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ÀÌ·¯ÇÑ ½ºÅÙÆ®¿¡ ´ëÇÑ È¯ÀÚµéÀÇ Àνİú ¼ö¿ëµµ°¡ ³ô¾ÆÁø µ¥´Ù ÀϺΠÁö¿ªÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥°ú °áÇÕÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© Çö´ë ½ÉÇ÷°ü Ä¡·á ÆÐ·¯´ÙÀÓ¿¡¼­ »ýüÈí¼ö¼º ½ºÅÙÆ®ÀÇ ¿ªÇÒÀÌ È®´ëµÇ°í ÀÖÀ½À» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¿ä 25°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bioresorbable Stents Market to Reach US$1.2 Billion by 2030

The global market for Bioresorbable Stents estimated at US$554.4 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Growth in the Metal-based Bioresorbable Stents segment is estimated at 10.2% CAGR over the analysis period.

Global Bioresorbable Stents Market - Key Trends & Drivers Summarized

Bioresorbable stents, also known as bioresorbable vascular scaffolds (BVS), represent a significant advancement in interventional cardiology. These stents are designed to provide temporary support to the artery after a procedure, gradually dissolving over time and leaving behind a natural vessel. Unlike traditional metal stents, which remain permanently in the body, bioresorbable stents are composed of materials like polylactic acid (PLA) that naturally break down and are absorbed by the body. This temporary nature reduces the long-term risks associated with permanent implants, such as chronic inflammation and late-stage thrombosis. Clinical trials have demonstrated the efficacy of bioresorbable stents in treating coronary artery disease, showing comparable outcomes to metallic stents with the added benefit of restoring the vessel's natural function and flexibility over time.

The development of bioresorbable stents has been propelled by extensive research and technological innovations. These stents are engineered to provide the necessary mechanical support to the artery during the critical healing period post-angioplasty. Over time, the stent gradually degrades, reducing the risk of long-term complications. Additionally, bioresorbable stents are often coated with antiproliferative drugs to further prevent restenosis, or re-narrowing of the artery. This dual function of providing mechanical support and drug delivery enhances the therapeutic outcomes for patients. Furthermore, the use of advanced imaging techniques and precision engineering has improved the deployment and efficacy of these stents, making them a viable option for a broader range of patients and clinical scenarios.

The growth in the bioresorbable stents market is driven by several factors. Firstly, there is an increasing prevalence of cardiovascular diseases globally, particularly coronary artery disease, which necessitates effective and innovative treatment options. Secondly, the rising demand for minimally invasive procedures among patients and healthcare providers is fueling the adoption of bioresorbable stents. These stents offer a promising alternative to traditional methods, aligning with the trend towards less invasive interventions. Thirdly, technological advancements in biomaterials and stent design are enhancing the performance and safety profile of bioresorbable stents, making them more attractive to clinicians. Lastly, the growing awareness and acceptance of these stents among patients, coupled with favorable reimbursement policies in several regions, are further boosting market growth. The confluence of these factors underscores the expanding role of bioresorbable stents in modern cardiovascular treatment paradigms.

Select Competitors (Total 25 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â